Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
2345 results:
1. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract] [Full Text] [Related]
2. [Chinese expert consensus on maintenance treatment with anti-egfr monoclonal antibody for
Committee of Colorectal Experts, Chinese Society of Clinical Oncology
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):316-325. PubMed ID: 38644236
[TBL] [Abstract] [Full Text] [Related]
3. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
4. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
6. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract] [Full Text] [Related]
7. [History and Perspective of Chemotherapy in Advanced Esophageal cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract] [Full Text] [Related]
8. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
9. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
[TBL] [Abstract] [Full Text] [Related]
10. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
11. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Yoshino T; Hooda N; Younan D; Muro K; Shitara K; Heinemann V; O'neil BH; Herrero FR; Peeters M; Soeda J; Suh M; Reichert H; Mezzi K; Fryzek J; Chia V; Rehn M; Stintzing S
Eur J Cancer; 2024 May; 202():113975. PubMed ID: 38442645
[TBL] [Abstract] [Full Text] [Related]
12. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
13. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
[TBL] [Abstract] [Full Text] [Related]
14. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
[TBL] [Abstract] [Full Text] [Related]
15. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with egfr monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
[TBL] [Abstract] [Full Text] [Related]
16. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the egfr/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract] [Full Text] [Related]
17. Association of RNF43 Genetic Alterations With BRAF
Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
[TBL] [Abstract] [Full Text] [Related]
18. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract] [Full Text] [Related]
19. Update on Targeted Therapy and Immunotherapy for Metastatic colorectal cancer.
Underwood PW; Ruff SM; Pawlik TM
Cells; 2024 Jan; 13(3):. PubMed ID: 38334637
[TBL] [Abstract] [Full Text] [Related]
20. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
[TBL] [Abstract] [Full Text] [Related]
[Next]
